ZhuZhou QianJin Pharmaceutical (600479) Fundamentals 2026 — P/E 14.4x, Revenue Analysis | SniperIQ
ZhuZhou QianJin Pharmaceutical (600479) is a CN-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of ¥3.9B, trading at ¥9.63 on the SHH. This SniperIQ fundamentals page covers ZhuZhou QianJin Pharmaceutical's valuation (P/E 14.4x, P/B 1.5x), profitability (net margin 8.6%), revenue (¥3.6B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is ZhuZhou QianJin Pharmaceutical's market cap?
ZhuZhou QianJin Pharmaceutical (600479) has a market capitalization of approximately ¥3.9B, trading at ¥9.63 on the SHH. Market cap moves with the live share price.
What is ZhuZhou QianJin Pharmaceutical's P/E ratio?
ZhuZhou QianJin Pharmaceutical's trailing twelve-month P/E ratio is 14.4x, with a price-to-book (P/B) of 1.5x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is ZhuZhou QianJin Pharmaceutical?
ZhuZhou QianJin Pharmaceutical runs a net profit margin of 8.6%, a gross margin of 101.0%, and an operating margin of 12.7%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does ZhuZhou QianJin Pharmaceutical generate?
ZhuZhou QianJin Pharmaceutical reported revenue of ¥3.6B for fiscal year 2025, with net income of ¥286M and earnings per share (EPS) of 0.64. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does ZhuZhou QianJin Pharmaceutical pay a dividend?
ZhuZhou QianJin Pharmaceutical offers a trailing dividend yield of about 3.9%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is ZhuZhou QianJin Pharmaceutical financially healthy?
ZhuZhou QianJin Pharmaceutical carries a debt-to-equity ratio of 0.02x and a current ratio of 1.48x, with a market beta of 0.26. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is ZhuZhou QianJin Pharmaceutical a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For ZhuZhou QianJin Pharmaceutical (600479) the key facts are: market cap ¥3.9B, P/E 14.4x, revenue ¥3.6B, 52-week range 9.2-11.53. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track ZhuZhou QianJin Pharmaceutical's full fundamentals live
Get ZhuZhou QianJin Pharmaceutical's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.